


CLAIM LISTING

Claim 1 (Previously Presented): A method for promoting colon adenocarcinoma cell differentiation, comprising treating a colon adenocarcinoma cell with a bilin.

Claims 2-9 (Cancelled)

Claim 10 (Previously Presented): A method for promoting differentiation of a colon adenocarcinoma cell, comprising treating a colon adenocarcinoma cell with a bilin represented by the general formula (I):



wherein W represents $-\text{CL}_2-$, $-\text{C}(=\text{O})-$, $-\text{C}(=\text{S})-$, $-\text{C}(=\text{NH})-$, or $=\text{CL}-$;

X represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

Y represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

Z represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

A represents $-\text{NH}-$ or $-\text{N}=-$;

B represents a trisubstituted, sp^2 -hybridized carbon atom;

K represents $=\text{CL}-$ or $-\text{CL}_2-$; and

L represents H or lower alkyl.

Claims 11-13 (Cancelled)

USSN 09/977,866

3

Facsimile Filing may 20, 2004

Claim 14 (Original): The method of claim 10, wherein the cell is contacted with the bilin *in vitro*.

Claim 15 (Original): The method of claim 10, wherein the cell is contacted with the bilin *in vivo*.

Claim 16 (Previously Presented): The method of claim 15, wherein the bilin is administered as part of a therapeutic application.

Claim 17 (Cancelled)

Claim 18 (Cancelled)

Claim 19 (Cancelled)

Claim 20 (Currently Amended): A method for promoting colon adenocarcinoma cell differentiation ~~A method for treating unwanted cell proliferation~~, comprising administering to a patient ~~a~~ [[the]] pharmaceutical preparation of ~~claim 18 or 19~~ comprising a sterile pharmaceutical excipient and a bilin.


Claim 21 (Original): The method of claim 1, wherein the bilin is bilirubin or biliverdine.

Claim 22 (Cancelled)

Claim 23 (Original): The method of claim 10, wherein the bilin is bilirubin or biliverdine.

Claim 24 (Cancelled)

Claim 25 (New): A method for promoting colon adenocarcinoma cell differentiation, comprising administering to a patient a pharmaceutical preparation comprising a sterile pharmaceutical excipient and a bilin represented by the general formula (I):



wherein W represents $-\text{CL}_2-$, $-\text{C}(=\text{O})-$, $-\text{C}(=\text{S})-$, $-\text{C}(=\text{NH})-$, or $=\text{CL}-$;

X represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

Y represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

Z represents a substituted or unsubstituted alkyl, alkenyl, or alkynyl group;

A represents $-\text{NH}-$ or $-\text{N}=-$;

B represents a trisubstituted, sp^2 -hybridized carbon atom;

K represents $=\text{CL}-$ or $-\text{CL}_2-$; and

L represents H or lower alkyl.